Review
Open access
Aug 2026
KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies
The recent approval of covalent KRAS G12C inhibitors, sotorasib and adagrasib, has revealed that targeted KRAS blockade can remodel the TME toward an immunostimulatory state, providing a mechanistic rationale for combining KRAS-directed agents with immune checkpoint blockade, STING agonists, and neoantigen vaccines.
Vasudevan Ramachandran, H. L. Koyou, Siddarth Raajasekar et al.
· Frontiers in Oncology · 0 citations